Genovis (GENO) Q2 2025 earnings summary

Executive summary

• Organic growth of 28% in Q2 2025 for the enzyme business, with EBIT doubling year-over-year, despite currency headwinds from a stronger SEK against USD and EUR.

• Growth was strong across North America, Europe, and Asia, with large pharma driving demand; smaller biotech activity remained subdued due to venture capital constraints.

• Strategic expansion through the acquisition of SEQURNA AB and an expanded licensing agreement with Thermo Fisher Scientific, strengthening presence in genomics and ADC markets.

Financial highlights

• Q2 2025 net sales for the enzyme business reached SEK 28,871 thousand, up 17% year-over-year (28% currency-adjusted); total net sales including divested antibody business fell 2%.

• Q2 2025 EBITDA for the enzyme business was SEK 6,036 thousand (up from SEK 3,796 thousand); EBIT was SEK 3,457 thousand (up from SEK 1,739 thousand).

• H1 2025 net sales for the enzyme business were SEK 61,163 thousand, up 21% year-over-year (24% currency-adjusted); total net sales including divested antibody business and license revenue decreased 12%.

• H1 2025 EBITDA for the enzyme business was SEK 14,943 thousand (up from SEK 12,089 thousand); EBIT was SEK 9,848 thousand (up from SEK 8,072 thousand).

• Profit for H1 2025 was SEK 8,573 thousand, with EPS of SEK 0.13 (down from SEK 0.22 year-over-year).

Outlook and guidance

• Despite macroeconomic and geopolitical uncertainty, underlying demand drivers in life sciences remain strong; company expects continued growth through product innovation and strategic investments.

• Management maintains a positive outlook for 2025, with operational capacity and business opportunities assessed as good, though external risks persist.